111, Inc. (NASDAQ:YI) Short Interest Down 54.5% in March

111, Inc. (NASDAQ:YI) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 3,000 shares, a decline of 54.5% from the March 15th total of 6,600 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average trading volume of 41,200 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 111 in a research report on Tuesday, April 8th.

Institutional Trading of 111

Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after acquiring an additional 305,339 shares during the last quarter. Napean Trading & Investment Co Singapore PTE Ltd acquired a new position in shares of 111 during the 4th quarter valued at about $245,000. Finally, FIL Ltd purchased a new position in 111 during the fourth quarter worth approximately $450,000. 21.32% of the stock is owned by institutional investors and hedge funds.

111 Stock Performance

YI stock traded up $0.19 during trading on Friday, reaching $7.50. 1,855 shares of the company traded hands, compared to its average volume of 23,149. The business has a 50 day simple moving average of $8.28 and a 200 day simple moving average of $7.52. The company has a market capitalization of $64.14 million, a price-to-earnings ratio of -1.88 and a beta of 0.57. 111 has a 12 month low of $4.15 and a 12 month high of $14.10.

111 (NASDAQ:YI) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter. The company had revenue of $527.14 million during the quarter.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.